Your doctor prescribed Wegovy because it's the right treatment for you. Your insurer disagreed. And if you're wondering whether it's even worth fighting back, it is, and this guide will show you exactly how.

Wegovy denials are extremely common, especially for the weight management indication. The 2025 KFF Employer Health Benefits Survey found that a majority of large employers (57%) still don't cover GLP-1 medications for weight loss. Even among the biggest firms (5,000+ workers), only 43% offer coverage. On ACA Marketplace plans, roughly 1% of formularies include Wegovy. The coverage gaps amount to a public health problem hiding behind paperwork. Nearly half of patients abandon treatment entirely after a denial, walking away from medications their doctors determined they need.

What the insurance industry doesn't expect is for you to do something about it. Fewer than 1% of denied claims ever get appealed, a statistic that saves insurers billions every year. But that number says more about how confusing the appeals process is than how hopeless it is. When patients actually push back with the right evidence, overturn rates are dramatically higher. We see this every day: Claimable's appeals succeed over 80% of the time in established conditions.

Knowing what kind of denial you're dealing with matters, because the strategy for overturning a blanket plan exclusion looks nothing like the strategy for a step therapy requirement or a documentation gap. This guide covers all of them, including the specific denial types, the clinical and legal arguments that win, and the exact steps to build an appeal that gets results.

Why Insurance Companies Deny Wegovy Coverage

Before you do anything else, you need to understand the specific reason your insurer denied coverage. The evidence you gather, the arguments you make, and the escalation path you follow all depend on this. Misidentifying your denial type is one of the fastest ways to waste a limited appeal opportunity.

What We See Across Thousands of Appeals

Denial letters are written in insurer language designed to sound final. They're not. Here's how to decode the most common denial types, what they actually mean for your situation, and where to start:

Blanket Plan Exclusion Denials

This is the denial type that makes people feel the most stuck, and understandably so. Your plan made a cost decision, not a clinical one. But Wegovy's FDA-approved label now extends well beyond weight management, covering cardiovascular risk reduction, MASH with liver fibrosis, and (as of March 2026) a higher 7.2 mg dose. A weight loss exclusion still leaves several doors open.

Your options:

Employer-sponsored plans: Talk to HR directly. Many employers adopted these exclusions before the cardiovascular and MASH data existed, and some are willing to revisit the policy, particularly when presented with the SELECT trial evidence showing Wegovy reduces the risk of heart attack, stroke, and cardiovascular death. Frame the request around healthcare outcomes and long-term cost avoidance, not "weight loss coverage."

The cardiovascular pathway: If you have established cardiovascular disease (previous heart attack, stroke, or peripheral arterial disease), Wegovy's CV indication may fall outside the weight loss exclusion entirely. This is the only weight management medication with this FDA approval, and it creates a distinct clinical category from weight management. This pathway is also relevant for Medicare Part D: the Treat and Reduce Obesity Act, signed into law in late 2025, requires Part D plans to cover at least one FDA-approved anti-obesity medication effective April 2026, and Wegovy's CV indication may offer an even earlier coverage pathway for beneficiaries with established heart disease.

The MASH pathway: If you have metabolic dysfunction-associated steatohepatitis with liver fibrosis, Wegovy is FDA-approved for this condition as of August 2025. A MASH-coded prescription is a different clinical category from a weight management prescription, and your plan may cover liver disease treatments even while excluding weight loss drugs.

Self-pay options while you appeal: Novo Nordisk offers Wegovy through NovoCare Pharmacy while you appeal. The oral pill starts at $149/month for starting doses. For injections, new patients can access starting doses at $199/month for their first two fills (offer available through June 30, 2026), then $349/month for standard doses or $399/month for the higher-dose Wegovy HD 7.2 mg. The Wegovy savings program can further reduce costs for commercially insured patients.

Not Medically Necessary Denials

This denial rarely reflects a genuine clinical judgment. It usually means the PA submission lacked documentation, and it's one of the most commonly overturned denial types on appeal.

What a strong submission includes: your baseline BMI before starting any treatment (not your current weight if medication has already helped, since insurers will use a lower number against you), a full accounting of comorbidities, prior weight loss interventions, relevant lab work, and a clear clinical rationale for why Wegovy specifically is the appropriate treatment.

Initial PA submissions are frequently bare-bones because prescribers are pressed for time. That 15-minute appointment doesn't leave much room for the kind of documentation that moves an insurer. If yours was thin, a resubmission with thorough documentation can change the outcome entirely.

Step Therapy Denials

Step therapy is the insurer's way of making you prove that cheaper options failed before they'll pay for the one your doctor actually prescribed. For Wegovy, that usually means trying Contrave, Saxenda, or phentermine, and some plans also require a formal weight management program.

The critical detail most patients miss: "failure" has a broad medical definition that works in your favor. You don't have to prove the medication did literally nothing. Intolerable side effects (heart palpitations on phentermine, nausea on Saxenda, mood changes on Contrave) count. So does a contraindication based on your medical history, even if you never took a single dose, and so does a weight management program that didn't produce or sustain clinically meaningful results.

The argument that wins: If there's a legitimate clinical reason the required alternatives are inappropriate, your doctor can request a step therapy exception. This argument is strongest if you have cardiovascular disease, since Wegovy is the only weight management medication with proven CV risk reduction from the SELECT trial. Nothing else in the step therapy chain carries that indication.

If you haven't tried the required alternatives and they're medically appropriate for you, completing the step therapy and documenting the results is sometimes the fastest path to approval.

Not on Formulary Denials

Every plan has a list of "preferred" drugs, and yours doesn't include Wegovy. This is typically a business decision about which drugs the insurer has negotiated pricing for.

The argument that wins: Request a formulary exception. Every insurer is required to have a process for non-formulary drugs that are medically necessary. Your case is stronger if you can show the formulary alternatives failed, caused side effects, are contraindicated, or don't cover a clinical need that Wegovy's label supports (cardiovascular risk reduction, MASH, or the specific weight management profile you need).

Sometimes the issue is that the insurer would prefer you take a different GLP-1 rather than rejecting Wegovy outright. If that's your situation, the clinical differentiation matters: document your response to Wegovy, any cardiovascular history or risk factors, and your prescriber's clinical rationale for why Wegovy specifically is the right choice. If you've already been stable on Wegovy and responding well, that continuity of care strengthens your case further.

One important detail: if your pharmacy benefits are managed by CVS Caremark, Wegovy has been their preferred GLP-1 for weight management since July 2025. If you're still getting a formulary denial through CVS Caremark, the block is likely coming from your employer's plan design, not the PBM, which means the conversation needs to happen with HR.

PA Requirements Not Met

This denial means the insurer claims you didn't meet one or more of their coverage requirements. Those rules may include BMI thresholds (typically 30 or higher, or 27 or higher with a comorbidity), weight management program participation, prior medication attempts, or specific comorbidity documentation.

That doesn't always mean you actually fail the criteria. Insurers sometimes apply rules incorrectly, overlook submitted documentation, or enforce requirements that exceed what medical evidence supports. Review each criterion against your actual records and address any gaps or misapplied rules directly in your appeal.

How to Appeal a Wegovy Denial: Step by Step

A denial is an opening position, and the appeals process exists specifically because denials are often wrong.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include: the specific reason for denial, your appeal rights, and the deadline to file.

Find your deadline first. Most commercial plans give 180 days, but there are exceptions: UnitedHealthcare allows just 65 days for many plan types, and Medicare Advantage plans follow CMS guidelines of 60 days. Missing the deadline means you won't be allowed to appeal, so move quickly.

Step 2: Know That You Have Your Own Appeal Rights On Top of Your Doctor's

Your provider can (and should) appeal on the clinical side by resubmitting documentation, writing a letter of medical necessity, and requesting peer-to-peer review. But you also have the right to file your own appeal as the patient, and it runs on a separate track with its own protections.

Why this matters: Patient-initiated appeals come with guaranteed response timelines, external review rights, and multiple appeal levels that provider-level appeals may not offer. Use both tracks: your doctor makes the clinical case while you exercise your independent rights. If your prescriber's prior authorization was denied, that doesn't close the door on your side of the process.

Step 3: Get a Letter of Medical Necessity

A letter of medical necessity (LMN) from your prescribing physician is the single most important document in your appeal package.

What a strong LMN includes: your diagnosis codes and clinical history, baseline BMI and weight trajectory, documented comorbidities (with cardiovascular disease, MASH, sleep apnea, and prediabetes being especially relevant for Wegovy appeals), a summary of prior treatments and why they were insufficient, supporting clinical evidence like the STEP trials for weight management, the SELECT trial for cardiovascular outcomes, and the ESSENCE trial for MASH, and a clear explanation of why Wegovy specifically, rather than just "a GLP-1," is the right choice.

How to ask: Be direct with your doctor. "My insurance denied Wegovy. Would you be willing to write a letter of medical necessity for my appeal? I can provide information on what the insurer typically looks for." If your doctor's office hasn't written many of these, offering to share a template can improve the quality and completeness of the letter.

Step 4: Build Your Appeal Package

A complete submission should include a cover letter summarizing your request, the LMN, supporting clinical documentation (labs, visit notes, cardiovascular risk profile, weight history), and a personal statement describing how the denial has affected your health and daily life.

A winning appeal brings together three elements:

Your story: How your condition affects your ability to work, sleep, and care for your family. If you have cardiovascular disease, what it means to be denied a medication proven to reduce heart attack and stroke risk. Reviewers are people; give them context that data alone can't convey.

Clinical evidence: Reference the relevant trials from the FDA Profile section below: STEP 1 for weight management, SELECT for cardiovascular risk reduction, ESSENCE for MASH, STEP UP for the higher-dose 7.2 mg option, or OASIS 4 for the oral formulation. Match the evidence to your specific situation and indication.

Policy and legal analysis: How your situation meets your plan's own coverage criteria, relevant state laws, and federal protections like the ACA's appeal and external review requirements. If the insurer's denial contradicts their published criteria or ignores submitted documentation, call it out specifically.

Step 5: Submit and Track

For internal appeals: Submit to your insurer per the instructions in your denial letter. They're required to respond within 30 days for standard appeals (72 hours for urgent/expedited appeals).

Keep records: Document when you submitted, how (fax, mail, portal), confirmation numbers, and the name of anyone you speak with. Insurers lose things. Having a paper trail protects you.

Step 6: Escalate If Needed

A denied internal appeal isn't the end. You have the right to request an external review by an independent reviewer who has no relationship with the insurer. External reviews evaluate the clinical merits of the denial against objective evidence, not the insurer's internal cost calculations, and they regularly overturn denials.

Other escalation options include filing a complaint with your state's Department of Insurance, exploring additional legal options for employer-sponsored ERISA plans, or escalating to the Office of Personnel Management for federal employee plans.

Don't give up after one "no." The system is designed to make you quit. Persistence is part of the strategy.

Wegovy's Expanding FDA Profile: Why It Matters for Your Appeal

Wegovy now has a broader FDA-approved label than any other GLP-1 for weight management, and that broader label gives you more angles in an appeal.

Chronic weight management (approved June 2021): For adults with obesity (BMI of 30 or higher) or overweight with at least one comorbidity (BMI of 27 or higher), and for adolescents aged 12 and older with obesity. The STEP 1 trial demonstrated nearly 15% average body weight loss at 68 weeks, with more than 86% of participants losing at least 5% and roughly one-third losing 20% or more.

Cardiovascular risk reduction (approved March 2024): For adults with established cardiovascular disease and either obesity or overweight, to reduce the risk of heart attack, stroke, and cardiovascular death. Based on the SELECT trial, which enrolled over 17,600 participants across 41 countries and showed a 20% reduction in major adverse cardiovascular events. No other weight management medication carries this indication.

MASH (approved August 2025): For adults with metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. First and only GLP-1 approved for this condition, based on the ESSENCE trial.

Higher dose / Wegovy HD (approved March 2026): The 7.2 mg injection, which demonstrated approximately 21% average weight loss over 72 weeks in the STEP UP trial, with over 90% of participants achieving at least 5% weight loss and about a third losing 25% or more. Available nationwide since April 2026.

Oral formulation / Wegovy pill (approved December 2025): Semaglutide 25 mg oral tablet, the first oral GLP-1 for chronic weight management and cardiovascular risk reduction. The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks among adherent participants. Available through pharmacies since January 2026, with self-pay pricing through NovoCare starting at $149/month for starting doses.

If your plan excludes weight loss drugs but covers cardiovascular treatment, the SELECT data opens a door. If you have MASH, you're dealing with a liver disease indication, not a weight loss one. And if your injectable Wegovy was denied, the oral formulation may face different coverage criteria.

How Long Does a Wegovy Appeal Take?

The single biggest factor in speed is completeness. Appeals that include everything (LMN, supporting documentation, personal statement, clinical evidence) move faster than submissions that trigger back-and-forth requests for additional information. In some cases, Claimable submits appeals to both internal and external review simultaneously to compress the timeline.

An Easier Path: Let Claimable Handle Your Appeal

If navigating this process feels overwhelming, or if you've been through a round of denials and need a stronger approach, Claimable can help.

Here's how it works: you answer a few questions about your Wegovy denial and medical history, and we build a fully customized appeal using our database of millions of clinical studies, insurer policies, and legal standards. The appeal package includes your personal narrative, clinical evidence matched to your specific situation, and a policy and legal analysis targeting your insurer's reasoning. We submit directly to your insurer and guide you through escalation if needed.

Thousands of GLP-1 appeals have taught us how each major insurer and PBM operates. We know which arguments work, which escalation paths are effective, and where the pressure points are.

Appealing with Claimable is $39.95 for Wegovy. No success fees, no hidden costs. For most patients, it's the difference between staying on a treatment that's working and abandoning it because the system made it too hard to fight.

Start your Wegovy appeal →

FAQs

Can I file my own appeal, or is that my doctor's job? Yes, and you should. Patient-initiated appeals run on a separate track from provider appeals with their own legal protections, mandated timelines, and external review rights. See Step 2 of the appeal guide above.

What's the difference between Wegovy and Ozempic? Same active ingredient (semaglutide), different FDA approvals and dosing. Wegovy is approved for chronic weight management (at 2.4 mg, 7.2 mg, and 25 mg oral), cardiovascular risk reduction, and MASH. Ozempic is approved for type 2 diabetes (at doses up to 2 mg). Insurance coverage often hinges on which diagnosis code is submitted; Ozempic gets approved more easily because diabetes indications face fewer coverage barriers.

Does Wegovy have a cardiovascular indication? Yes. It's the first and only weight management medication FDA-approved to reduce the risk of heart attack, stroke, and cardiovascular death, based on the SELECT trial. This indication can unlock coverage pathways that weight management alone cannot, including Medicare Part D, which now covers at least one anti-obesity medication under the Treat and Reduce Obesity Act effective April 2026.

Is there an oral version of Wegovy? Yes, approved December 2025 and available since January 2026. The OASIS 4 trial showed 16.6% mean weight loss at 64 weeks among adherent participants. Self-pay pricing starts at $149/month through NovoCare. If your injectable Wegovy was denied, the oral form may face different coverage criteria, so it's worth exploring both.

What if my plan won't cover any weight loss drugs? Wegovy's multi-indication label creates workarounds. The cardiovascular risk reduction indication, the MASH indication, and direct employer conversations are all viable pathways. See the Blanket Plan Exclusion section above for specifics.

How long do I have to file an appeal? Deadlines vary by insurer and are listed in your denial letter. Most commercial plans allow 180 days, but UnitedHealthcare allows just 65 days for many plan types, and Medicare Advantage allows 60 days. Regardless of how much time you have, moving quickly is always the better strategy.

What's the difference between Wegovy and Zepbound? Different drugs with different mechanisms. Wegovy (semaglutide) targets the GLP-1 receptor. Zepbound (tirzepatide) targets both GIP and GLP-1 receptors. Wegovy has cardiovascular risk reduction and MASH indications that Zepbound does not. CVS Caremark prefers Wegovy on its formularies; other PBMs may prefer Zepbound. Your appeal should be built around the specific drug your doctor prescribed and the clinical reasoning behind that choice.

Is it worth appealing? Almost always, yes. Fewer than 1% of denials are ever challenged, and insurers have built their entire denial infrastructure around that number. Appeals exist because the initial decision is frequently wrong, incomplete, or based on criteria the insurer misapplied. If your doctor prescribed Wegovy, there's a clinical reason, and the appeal gives you the chance to put that reasoning, backed by evidence, legal protections, and your own story, in front of someone who has to actually evaluate it.

Claimable's physician-led team has recovered over $30 million in care value for patients facing insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how we work →